Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies

BMC Systems Biology

Volumn 5, Issue , 2011, Pages

  Finley, Stacey D ^a   Engel Stefanini, Marianne O ^a   Imoukhuede, PI ^a   Popel, Aleksander S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEUROPILIN 2; NEUTRALIZING ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BREAST TUMOR; CELL CULTURE; CELL LINE; COMPUTER SIMULATION; DRUG ANTAGONISM; FEMALE; HUMAN; IMMUNOLOGY; KINETICS; METABOLISM; MOUSE; PHYSIOLOGY; SYSTEMS BIOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE; CELLS, CULTURED; COMPUTER SIMULATION; FEMALE; HUMANS; KINETICS; MICE; MODELS, BIOLOGICAL; NEUROPILIN-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SYSTEMS BIOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81355160889     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-5-193     Document Type: Article

References (60)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936. 10.1038/nature04478, 16355210.
2. Egginton S. Invited review: activity-induced angiogenesis. Pflugers Archiv (European Journal of Physiology) 2009, 457:963-977.
3. Sung H-K, Michael IP, Nagy A. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Curr Opin Hematol 2010, 17:206-212.
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307. 10.1038/nature10144, 21593862.
5. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007, 97:978-985. 10.1038/sj.bjc.6603923, 2360423, 17912242.
6. Niers TM, Richel DJ, Meijers JC, Schlingermann RO. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS ONE 2011, 6:e19873. 10.1371/journal.pone.0019873, 3102663, 21637343.
7. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10:417-427. 10.1038/nrd3455, 21629292.
8. Hiratsuka S. Vasculogenesis, angiogenesis and special features of tumor blood vessels. Front Biosci 2011, 16:1413-1427. 10.2741/3796, 21196239.
9. Rosca E, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS. Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 2011, 12:1101-1116. 10.2174/138920111796117300, 3114256, 21470139.
10. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 2007, 39:1349-1357. 10.1016/j.biocel.2007.04.010, 2752727, 17537667.
11. Ivy SP, Wichk JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009, 6:569-579. 10.1038/nrclinonc.2009.130, 19736552.
12. Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: Anti-angiogneic therapy in the treatment of cancer. Mol Aspects Med 2011, 32:88-111. 10.1016/j.mam.2011.04.004, 21565214.
13. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67. 10.1016/j.cell.2010.03.015, 2862057, 20371345.
14. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation 2008, 15:715-738. 10.1080/10739680802095964, 2722038, 18608994.
15. Qutub AA, Mac Gabhann F, Karagiannis ED, Vempati P, Popel AS. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag 2009, 28:14-31.
16. Byrne HM. Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer 2010, 10:221-230. 10.1038/nrc2808, 20179714.
17. Anderson ARA, Quaranta V. Integrative mathematical oncology. Nat Rev Cancer 2008, 8:227-234. 10.1038/nrc2329, 18273038.
18. Peirce SM. Computational and mathematical modeling of angiogenesis. Microcirculation 2010, 15:739-751.
19. Stefanini MO, Qutub AA, Gabhann FM, Popel AS. Computational models of VEGF-associated angiogenic processes in cancer. Math Med Biol
20. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Systems Biology 2008, 2:77. 10.1186/1752-0509-2-77, 2562372, 18713470.
21. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 2010, 70:9886-9894. 10.1158/0008-5472.CAN-10-1419, 21118974.
22. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: Expression, regulation, and function. Exp Cell Res 2006, 312:584-593. 10.1016/j.yexcr.2005.11.024, 16445911.
23. Padera TP, Kadambi A, Di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, et al. Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics. Science 2002, 296:1883-1886. 10.1126/science.1071420, 11976409.
24. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Res 2000, 60:4324-4327.
25. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbah C, Lin AS, Guldberg RE, Mooney DJ. Integrated approach to designing growth factor delivery systems. FASEB J 2007, 21:3896-3903. 10.1096/fj.06-7873com, 17644610.
26. Serini G, Ambrosi D, Giraudo E, Gamba A, Preziosi L, Bussolino F. Modeling the early stages of vascular network assembly. EMBO J 2003, 22:1771-1779. 10.1093/emboj/cdg176, 154468, 12682010.
27. Kleinheinz J, Jung S, Wermker K, Fischer C, Joos U. Release kinetics of VEGF165 from a collagen matrix and structural matrix changes in a circulation model. Head Face Med 2010, 6.
28. McKinney-Freeman SL, Jackson KA, Camargo FD, Ferrari G, Mavilio F, Goodell MA. Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proc Natl Acad Sci USA 2002, 99:1341-1346. 10.1073/pnas.032438799, 122192, 11830662.
29. van Beijnum JR, Rousch M, Castermans K, van der Linden E, Griffioen AW. Isolation of endothelial cells from fresh tissues. Nat Protoc 2008, 3:1085-1094. 10.1038/nprot.2008.71, 18546599.
30. Majka SM, Jackson KA, Kienstra KA, Majesky MW, Goodell MA, Hirschi KK. Distinct progenitor populations in skeletal muscle are bone marrow derived and exhibit different cell fates during vascular regeneration. J Clin Invest 2003, 111:71-79. 151835, 12511590.
31. Imoukhuede PI, Popel AS. Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Exp Cell Res 2011, 317:955-965. 10.1016/j.yexcr.2010.12.014, 3073416, 21185287.
32. Geretti E, Shimizu A, Kurschat P, Klagsbrun M. Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F. J Biol Chem 2007, 284:25698-25707.
33. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J Biol Chem 2000, 275:18040-18045. 10.1074/jbc.M909259199, 10748121.
34. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. PLoS Comp Biol 2009, 5:e1000622.
35. Pilch H, Schlenger K, Steiner E, Brockerhoff P, Knapstein P, Vaupel P. Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int J Gynecol Cancer 2001, 11:137-142. 10.1046/j.1525-1438.2001.011002137.x, 11328412.
36. Leith JT, Michelson S. Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumour cells as a function of oxygen concentration. Cell Prolif 1995, 28:415-430. 10.1111/j.1365-2184.1995.tb00082.x, 7548442.
37. Salnikov AV, Heldin N-E, Stuhr LB, Wiig H, Gerber H-P, Reed RK, Rubin K. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer 2006, 119:2795-2802. 10.1002/ijc.22217, 17019708.
38. Rofstad EK, Halsor EF. Vascular endothelial growth factor, Interleukin 9, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000, 60:4932-4938.
39. Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment?. Fibrogenesis Tissue Repair 2010, 3:12. 10.1186/1755-1536-3-12, 2920231, 20653943.
40. Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res 2002, 8:2253-2259.
41. Yuan A, Yu CJ, Luh KT, Lin FY, Kuo SH, Yang PC. Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR. Lab Invest 2000, 2000:11.
42. Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 1998, 29:910-914. 10.1016/S0046-8177(98)90195-2, 9744306.
43. Ljungberg B, Jacobsen J, Haggstrom-Rudolfssson S, Rasmuson T, Lindh G, Grankvist K. Tumor vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res 2003, 31:335-340. 10.1007/s00240-003-0346-x, 14574539.
44. Zygalaki E, Tsaroucha EG, Kaklamanis L, Lianidou ES. Quantitative real-time reverse transcription-PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non-small cell lung cancer. Clin Chem 2007, 53:1433-1439. 10.1373/clinchem.2007.086819, 17599955.
45. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001, 220:112-121. 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D, 11169844.
46. Gustafsson T, Ameln H, Fischer H, Sundberg CJ, Timmons JA, Jansson E. VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise. J Appl Physiol 2005, 98:2137-2146. 10.1152/japplphysiol.01402.2004, 15661835.
47. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
48. Segerstrom L, Fuchs D, Backman U, Holmquist K, Christofferson R, Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 2006, 60:576-581. 10.1203/01.pdr.0000242494.94000.52, 16988184.
49. Willet CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin S, Petit L, Jain RK, Chung DD, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139. 10.1200/JCO.2005.02.5635, 16258121.
50. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434. 10.1056/NEJMoa021491, 2275324, 12890841.
51. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121. 10.1152/physrev.00038.2010, 21742796.
52. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 å resolution and mutational analysis of the interface. Structure 1998, 6:1153-1167. 10.1016/S0969-2126(98)00116-6, 9753694.
53. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007, 104:3478-3483. 10.1073/pnas.0611492104, 1805509, 17360669.
54. Eremina V, Jefferson A, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, et al. VEGF inhibition and renal thrombotic microangiopathy. New Engl J Med 2008, 358:1129-1136. 10.1056/NEJMoa0707330, 3030578, 18337603.
55. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6:465-477. 10.1038/nrclinonc.2009.94, 19581909.
56. Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: comparison of therapeutic approaches. PLoS Comp Biol 2006, 2:e180.
57. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 2009, 106:16157-16162. 10.1073/pnas.0908201106, 2752543, 19805273.
58. Schneider BP, Sledge GW. Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?. J Clin Oncol 2011, 29:2444-2447. 10.1200/JCO.2011.34.9266, 21555698.
59. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62. 10.1126/science.1104819, 15637262.
60. Verheul HMW, Lolkema MPJ, Quian DZ, Hilkes YHA, Liapi E, Akkerman J-WN, Pili R, Voest EE. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007, 13:5341-5347. 10.1158/1078-0432.CCR-07-0847, 17855648.